PTPRC and cancer: For the study, CD45-negative cancer cells isolated from tumor biopsies of three patients (two with clear cell carcinoma [specimens #3662 and #3658] and one with high-grade serous carcinoma [specimen #3665]) were treated with OVV at an MOI of 1 (2 h) or DOX (1 μM for 1 h) alone in combination and analyzed by the end of the incubation period for nuclear translocation of CREB3L1 by ImageStream (Figure 6B).